Background {#Sec1}
==========

Birt-Hogg-Dubé syndrome (BHDS) is an autosomal dominant hereditary condition associated with skin lesions such as fibrofolliculoma, acrochordon and trichodiscoma, pulmonary lesions including spontaneous pneumothorax and pulmonary cysts and renal cancer. In 1925, Burnier and Rejsek reported an elderly female with multiple small skincolored papules on the head and neck, which was probably the first case of BHD \[[@CR1]\]. In 1960, Zackheim and Pinkus described five more cases with similar clinical manifestations and histopathologic features \[[@CR2]\]. In 1977, Birt, Hogg, and Dubé found that a few members of a thyroid cancer family had fibrofolliculoma that occurred in an autosomal dominant hereditary pattern \[[@CR3]\]. In 2001, the susceptible locus was localised to chromosome 17p11.2 \[[@CR4], [@CR5]\]. Subsequently, protein-truncating mutations were identified in the *FLCN* (BHD) gene comprising 14 exons and encoding a protein called folliculin with unknown function \[[@CR6]\]. Folliculin is expressed in most tissues including the skin and its appendages, the lungs (type 1 pneumocytes) and the kidney (distal nephron). Although the accurate function of this protein has not yet been clarified, it seems to be involved in the adenosine-monophosphate-activated protein kinase and mTOR pathways \[[@CR7], [@CR8]\]. Some studies have proved that downstream molecules of insufficient *FLCN* such as S6 kinase and hypoxia-inducible factor 1-alpha (HIF-1a) increases in renal tumors derived from BHDS patients. In the lung, cyst-lining cells were suggested to be activated due to their immunostaining positivity for phospho-mTOR and phospho-S6 ribosomal protein \[[@CR9]--[@CR12]\]. As neoplastic hyperplasia hardly occurs in cyst-lining cells, the mTOR pathway may be less distinctively detected in pulmonary cysts \[[@CR11]\].

More than 200 mutations in the *FLCN* gene have been identifed, most of which are frameshift, nonsense, missense, or splice site mutations. The most common mutation in patients with Birt-Hogg-Dubé syndrome is c.1285dupC located in exon 11 \[[@CR13]--[@CR22]\], followed by c.1533_1536delGATG \[[@CR12], [@CR15], [@CR23]--[@CR25]\] and c.1278dupC \[[@CR26]--[@CR29]\] depending on literatures listed worldwide up to date. Table [1](#Tab1){ref-type="table"} presents the mutations described in the *FLCN* gene up to now according to literatures summarized by searching "Birt-Hogg-Dubé syndrome" and "*FLCN*" on pubmed and Embase line.Table 1Germline mutations in Birt-Hogg-Dubé syndromeExon/IntronNucleotide changesAmino acid changesExon 1Exon1 deletionSplice mutationExon 1c.-487G \> CSplice mutationExon 1c.-302G \> ASplice mutationExon 1c.-299C \> TSplice mutationExon 1chr17:17080497_17087267del; 17084378_17084502invinsSplice mutationExon 1chr17:17078506_17084897delSplice mutationExon 1chr17:17080610_17086298del; insCCATGGGGGSplice mutationExon 2--5c.-227-853_c.397-295delSplice mutationExon 3c.-90A \> GSplice mutationExon 3c. − 84G \> ASplice mutationExon 4c.1A \> Gp.Met1ValExon 4c.3delGp.Met1XfsExon 4c.3G \> Ap.Met1?Exon 4c.50G \> Cp.Arg17ProExon 4c.57_58delCTp.Phe20XfsExon 4c.59delTp.Phe20XfsExon 4c.119delGp.Gly40XfsExon 4c.145G \> Tp.Glu49^a^Exon 4c.147delAp.Glu49XfsExon 4c.157C \> Tp.Gln53^a^Exon 4c.158delAp.Gln53XfsExon 4c.214delAp.Ser72XfsExon 4c.235_238delTCGGp.Ser79XfsExon 4c.240delCp.Asp80XfsExon 4c.241delAp.Met81XfsExon 5Deletion of Exon 5Protein truncationExon 5c.252delCp.Gly84XfsExon 5c.296delAp.Asp99XfsExon 5c.319_320delGTinsCAGp.Val107 deletion/ insertionExon 5c.319_320delGTinsCACp.Val107 deletion/ insertionExon 5c.323G \> T (778G \> T)p.Ser108IleExon 5c.328C \> Tp.Gln110^a^Exon 5c.332_349del(18nucleotides)p.His111_Gln116delXfsExon 5c.340dupCp.His114XfsExon 5c.347dupAp.Leu117XfsExon 5c.376delGp.Val126XfsExon 5c.394G \> Ap.Glu132LysExon 6c.402delCp.Pro135XfsExon 6c.404delCp.Pro135XfsExon 6c.420delCp.Ile141fsExon 6c.427_429delTTCp.Phe143delExon 6c.443_459delACGGCTTTGTGTTCAGCp.His148_153SerdelXfsExon 6c.469_471delTTCp.Phe157XfsExon 6c.499C \> Tp.Gln167^a^Exon 6c.510C \> Gp.Tyr170^a^Exon 6c.510C \> Ap.Tyr170^a^Exon 6c.553 T \> Cp.Ser185ProExon 6c.563delTp.Phe188XfsExon 6c.\[564_565dupCC;566_577delTGCTGGGGAAGG\]p.Leu189XfsExon 6c.573_574delinsTp.Lys192XfsExon 6c.581delGp.Gly195XfsExon 6c.583G \> Tp.Gly195^a^Exon 6c.584delGp.Gly195XfsExon 6c.601C \> Tp.Gln201^a^Exon 6c.610_611delinsTAp.Ala204^a^Exon 7c.632 633delAGinsCp.Glu211XfsExon 7c.637delTp.Phe213XfsExon 7c.649C \> Tp.Gln217^a^Exon 7c.655dupGp.Ala219XfsExon 7c.658C \> Tp.Gln220^a^Exon 7c.668delAp.Asn223XfsExon 7c.689dupTp.Leu230XfsExon 7c.671_672delCAp.Thr224XfsExon 7c.715C \> Tp.Arg239CysExon 7c.726A \> TNSExon 7c.769_771delTCCp.Ser257XfsExon 7c.770_772delCCTp.Ser257XfsExon 7c.747_756insGTGATGACAAp.Asn249XfsExon 7c.779G \> Ap.Trp260^a^Exons 7--14c.675-?\_c.^a^ +?delExon 8∆E8p.Trp260XfsExon 8c.836_839delCCGAp.Thr279XfsExon 8c.853C \> Tp.Gln285^a^Exon 9c.887C \> Ap.Ser296^a^Exon 9c.889_890delGAp.Glu297XfsExon 9c.890_893delp.Glu297XfsExon 9c.923_950dupFrameshiftExon 9c.932_933delCTp.Pro311XfsExon 9c.933delTp.Val312XfsExon 9c.943 G \> Tp.Glu315^a^Exon 9c.946_947delAGp.Ser316XfsExon 9c.991_992dupTCp.Leu332XfsExon 9c.997_998delTCp.Ser333XfsExon 9c.997_998dupTCp.Gly334XfsExon 9c.1013delGp.Trp338XfsExon 9c.1015C \> Tp.Gln339^a^Exon 9c.1018delCp.Arg341XfsExon 9c.1021delCp.Arg341XfsExons 9--14c.872-?\_c.1740 +? delProtein truncationExon 10c.1063 1065delGTCp.Val355XfsExon 10c.1067 T \> Cp.Leu356ProExon 10c.1076delCp.Pro359XfsExon 10c.1095C \> GNSExon 10c.1117C \> Tp.Gln373^a^Exon 10c.1127G \> Ap.Trp376^a^Exon 10c.1153 C \> Tp.Gln385^a^Exon 10c.1156_1175delFrameshiftExon 10c.1156_1176delFrameshiftExon 10c.1165G \> Tp.Glu389^a^Exon 10--11c.1063-154_1300 + 410dupExon 10 deletionExon 11c.1183_1198delFrameshiftExon 11c.1198G \> Ap.Val400IleExon 11c.1215C \> Gp.Tyr405^a^Exon 11c.1219delAp.Ser407XfsExon 11c.1228G \> Tp.Glu410^a^Exon 11c.1252delCp.Leu418XfsExon 11c.1269C \> TNSExon 11c.1278dupCp.His429XfsExon 11c.1278delCp.His429XfsExon 11c.1285dupCp.His429XfsExon 11c.1285delCp.His429XfsExon 11c.1285C \> Tp.His429TyrExon 11c.1286dupAp.His429XfsExon 11c.1294_1298delTCCTCp.Ser432XfsExon 11c.1300G \> ASplice mutationExon 11c.1300G \> CSplice mutationExon 12c.1301-7_1304del;1323delCinsGAFrameshiftExon 12c.1303delTp.Phe435XfsExon 12c.1305delTp.Phe435XfsExon 12c.1318 1334dupFrameshiftExon 12c.1323delCinsGAp.His442XfsExon 12c.1333G \> Ap.Ala445ThrExon 12c.1335_1351dupFrameshiftExon 12c.1337 1343dupFrameshiftExon 12c.1340 1346dupFrameshiftExon 12c.1347_1353dupCCACCCTFrameshiftExon 12c.1372dup (1827insC)p.Gln458XfsExon 12c.1379_1380delTCp.Leu460XfsExon 12c.1389C \> Gp.Tyr463^a^Exon 12c.1408_1418 insGGGAGCCCTGTFrameshiftExon 12c.1426dupGFrameshiftExon 12c.1429C \> Tp.Arg477^a^Exon 12CCACCCT insertionExon 13c.1487_1490dupFrameshiftExon 13c.1481A \> Gp.Asn494SerExon 13c.1489_1490delGTp.Val497XfsExon 13c.1490insCTGTFrameshiftExon 13c.1522_1524del AAGp.Lys508XfsExon 13c.1523A \> Gp.Lys508ArgExon 13c.1528_1530delGAGp.Glu510XfsExon 13c.1533G \> Ap.Trp511^a^Exon 13c.1533_1536delGATGp.Trp511^a^XfsExon 14c.1539-?\_c.1740 +? delExon14 deletionExon 14c.1552delCp.Leu518XfsExon 14c.1557delTp.Phe519XfsExon 14c.1579_1580insAp.Arg527XfsExon 14c.1579C \> Tp.Arg527^a^Exon 14c.1597_1598delCAp.Gln533XfsExon 14c.1645C \> Gp.Leu549ValExon 14c.1658G \> Ap.Trp553^a^Exon 14c.1677G \> ANSExon 14c.1715 + 16insC(14--22)Splice mutationExon 14c.1715 + 582 T \> CSplice mutationIntron1c.-228 + 1368G \> TSplice mutationIntron1c.-229 + 994A \> GSplice mutationIntron3c.-25 + 100C \> GSplice mutationIntron3c.1-64A \> GSplice mutationIntron 4c.249 + 1G \> TSplice mutationIntron 4c.250-2A \> GSplice mutationIntron 4c.250-1G \> ASplice mutationIntron 5c.396 + 1G \> ASplice mutationIntron 5c.396 + 59 T \> CSplice mutationIntron 5c.397-14C \> TSplice mutationIntron 5c.397-13G \> ASplice mutationIntron 5c.397-13_397-4delGGCCCTCCAGSplice mutationIntron 5c.397-10_397-2delGTCCCTCCASplice mutationIntron 5c.397-7_399delcctccagGTCSplice mutationIntron 5c.397-2A \> CSplice mutationIntron 5c.397-1G \> CSplice mutationIntron 5c.397-7_399delSplice mutationIntron5-Exon6cctccagGTCdeletionSplice mutationIntron6c.618 + 2 T \> ASplice mutationIntron6c.619-66C \> TSplice mutationIntron6c.619-1G \> ASplice mutationIntron 7c.779 + 1G \> TSplice mutationIntron 7c.779 + 113C \> TSplice mutationIntron 7c.780-1G \> TSplice mutationIntron8c.871 + 3_871 + 4delGAinsTCCAGATSplice mutationIntron8c.871 + 13 T \> CSplice mutationIntron8c.871 + 16 T \> ASplice mutationIntron8c.871 + 36G \> ASplice mutationIntron8c.871 + 204A \> GSplice mutationIntron8c.871 + 226G \> ASplice mutationIntron8c.871 + 684G \> ASplice mutationIntron 9c.1062 + 1G \> ASplice mutationIntron 9c.1062 + 2 T \> GSplice mutationIntron 9c.1062 + 5G \> ASplice mutationIntron 9c.1062 + 6C \> TSplice mutationIntron 9c.1062 + 47G \> ASplice mutationIntron 9c.1063-172C \> GSplice mutationIntron 9c.1063-117C \> TSplice mutationIntron9c.1063-10_1065delTCTTGTTTAGGTCExon 10 skipIntron 9c.1063-2A \> GSplice mutationIntron 10c.1176 + 31G \> ASplice mutationIntron 10c.1176 + 39G \> ASplice mutationIntron 10c.1176 + 68G \> CSplice mutationIntron 10c.1176 + 134G \> CSplice mutationIntron 10c.1176 + 179A \> GSplice mutationIntron 10c.1177-165C \> TSplice mutationIntron 10c.1177-8_1177-6delTCCSplice mutationIntron 10c.1177-5_1177-3delCTCSplice mutationIntron10c.1177-2A \> GSplice mutationIntron 11c.1300 + 2 T \> CSplice mutationIntron 11c.1301-59C \> TSplice mutationIntron 11c.1301-7del11; 1323delCinsGASplice mutationIntron 12c.1432 + 1G \> ASplice mutationIntron 12c.1432 + 4 C \> TSplice mutationIntron 12c.1433-38A \> GSplice mutationIntron 12c.1433-1G \> TSplice mutationIntron 13c.1538 + 121C \> TSplice mutationNS represented that the mutation was synonymous and the amino acid was not changedfs represented frameshift^a^designates a stop codon

Objectives {#Sec2}
----------

The aim of this study is to explore the genetic mutations of two suspected BHDS families, and to see if they could expand the spectrum of *FLCN* mutations.

Methods {#Sec3}
=======

The two BHDS families were recruited from Peking Union Medical College Hospital and Xiangya Hospital Central South University. Detailed physical examination and other relevant examination of the participants were carried out. Peripheral venous blood samples of the participants were collected with anticoagulant tubes, storage and transportation of which were under the condition of 4 °C, then genomic DNA was extracted from blood samples within 6 h for further gene analysis: The whole blood and erythrocyte lysate were mixed thoroughly, kept still on ice for about 30 min until clear and then centrifuged at 3000 rpm for 10 min (4 °C); abandoned the supernatant, and mixed the remnant with nuclear lysate. Then added proteinase K into the mixture and mixed them thoroughly until there was no cell precipitate. Added SDS and shook at 37°Cfor 6 h or overnight. Added saturated phenol, mixed well up and down and centrifuged at 3000 rpm for 10 min (4 °C). Then put the supernatant into the mixture of saturated phenol and chloroform (1: 1), mixed well up and down and centrifuged at 3000 rpm for 10 min (4 °C); after that, put the supernatant into chloroform, mixed thoroughly up and down and centrifuged at 3000 rpm for 10 min (4 °C). The supernatant was added to a centrifuge tube previously charged with ethanol, gently inverted it to precipitate the DNA. The DNA and a small amount of ethanol was transferred to an eppendorf tube finally and stored at −20 °C in reserve.

With clinical manifestations and family history of pneumothorax, the patients and some of their relatives were diagnosed with suspected BHDS, at the meantime, unaffected relatives were invited to participate as controls. Members II10, III8, III10, III11, III12, III13, III14, IV1, IV2, IV3, IV4 in family 1 and II1, III2 in family 2 were sequenced. Publication of all the medical data has obtained consent of the participants, and the propositi consented on behalf of the deceased patients to both participate and to have their data published.

We selected one patient from each family respectively (IV3 in family 1 and III2 in family 2), carrying out whole exome sequencing for mutation detection: The 300 ng genomic DNA concentrations were sheared with Covaris LE220 Sonicator (Covaris) to target of 150-200 bp average size. DNA libraries were prepared using SureselectXT reagent kit (Agilent). The fragments were repaired the 3′ and 5′ overhangs using End repair mix (component of SureselectXT) and purified using Agencourt AMPure XP Beads (Beckman). The purified fragments were added with'A' tail using A tailing Mix (component of SureSelectXT) and then ligated with adapter using the DNA ligase (component of SureselectXT). The adapter-ligated DNA fragments were amplified with Herculase II Fusion DNA Polymerase (Agilent). Finally, the pre-capture libraries containing exome sequences were captured using SureSelect capture library kit (Agilent). DNA concentration of the enriched sequencing libraries was measured with the Qubit 2.0 fluorometer dsDNA HS Assay (Thermo Fisher Scientific). Size distribution of the resulting sequencing libraries was analyzed using Agilent BioAnalyzer 2100 (Agilent). The libraries were used in cluster formation on an Illumina cBOT cluster generation system with HiSeq PE Cluster Kits (illumina). Paired-end sequencing is performed using an Illumina HiSeq system following Illumina-provided protocols for 2 × 150 paired-end sequencing. Then we applied Sanger sequencing aiming at corresponding exons in *FLCN* gene for subsequent validation of other family members roughly as follows: PCR amplification with appropriate primers on PCR amplifier - PCR cleanup in magnetic bead purification system - cycle sequencing on PCR amplifier - sequencing cleanup on magnetic bead purification platform - capillary electrophoresis on ABI3730. Interpretation of Sanger sequencing results was performed using SnapGene Software.

Results {#Sec4}
=======

Family 1 (F1) {#Sec5}
-------------

The proband, a 47-year-old woman with a 25-year history of left-lung-pneumothorax, has had her left lung partially resected. Moreover, she was diagnosed with cerebral infarction 3 years ago on account of right limb numbness and visual defect in the lower half of the right eye. In addition, two of her sisters and their sons (Fig. [1](#Fig1){ref-type="fig"}: III8, III12, IV1, IV3) also had spontaneous pneumothorax history at the age of 39, 48, 21 and 21 respectively, a maximum frequency of which was six times. Diffuse lesions of the thyroid gland, superficial lymph node enlargement of the neck and extremities and subcutaneous nodules of the head, neck and hands were also revealed in one of her sister (III8) after pulmonary bubble resection; computed tomography (CT) scans of the other sister (III12) who had a history of hysteromyoma excision ever showed double renal cysts, which disappeared 2 years later in the renal ultrasonic examination results. While one nephew (IV1) of the proband had fat granules on his face and neck, who once underwent right branchial cystectomy; the other nephew (IV3) was diagnosed with chronic pancreatitis at 11 years old. A few of her other family members (Fig. [1](#Fig1){ref-type="fig"}:II1, II4, II7, II9, II11; II9: cerebral hemorrhage, others: cerebral infarction) also suffered from stroke, all of whom have passed away. One died of thrombocythemia (Fig. [1](#Fig1){ref-type="fig"}:III1). (Fig. [2](#Fig2){ref-type="fig"}).Fig. 1Pedigre of family 1. ![](12881_2017_519_Figa_HTML.gif){#d29e2753} proband. ![](12881_2017_519_Figb_HTML.gif){#d29e2756} Cases with stroke. ![](12881_2017_519_Figc_HTML.gif){#d29e2759} Thrombocythemia CaseFig. 2Examination results and Sequence diagram of family 1. **a**, **b**, **c** Computed tomography scans showing multiple cystic lesions in the lungs of patients (III8、III12、III14). **b**, **e** Computed tomography scan and X-ray examination results showing pneumothorax (III8、IV3). **d** Fat granules on the skin (IV1). **f** Direct sequencing of exon 14 of *FLCN* revealed the frameshift mutation: c.1579_1580insA on exon 14

Family 2 (F2) {#Sec6}
-------------

A 26-year-old man with after-exercise pectoralgia was diagnosed pneumothorax with CT scans, and before that, he once had a pneumothorax attack. In his family members, his father and grandfather also had pneumothorax history, for which his father had a thoracoscopic surgery. Besides, his grandfather passed away because of nephropathy without concrete information (Figs. [3](#Fig3){ref-type="fig"} and [4](#Fig4){ref-type="fig"}). The clinical information of the two families are listed in Table [2](#Tab2){ref-type="table"}.Fig. 3Pedigre of family 2. ![](12881_2017_519_Figd_HTML.gif){#d29e2819} probandFig. 4Examination results and Sequence diagram of family 2. **a** Computed tomography scans showing pulmonary cyst and pneumothorax (III2). **b**, **c** Multiple pulmonary cysts and pneumothorax in the lung of the proband's father (II1). **d**, **e** Direct sequencing of exon7 of *FLCN* revealed the nonsense mutation: c.649C \> T on exon 7Table 2Summary of clinical information of the two familiesNumberFamilySexAgePneumothoraxPulmonary CystsSkin lesionKidney lesionMutation RegionIII8F1Female53YesYesSubcutaneous noduleNoExon 14III12F1Female48YesYesNoRenal cystsExon 14III14F1Female47YesYesNoNoExon 14IV1F1Male28YesNoFat granulesNoExon 14IV3F1Male21YesYesNoNoExon 14IV4F1Female18NoNoNoNoExon 14II1F2Male52YesYesNoNoExon 7III2F2Male26YesYesNoNoExon 7

Mutation examinations revealed that the proband, her two sisters, two nephews (III8, III12, IV1, IV3) and her son (IV4) in F1 all carried a one-base (A) -insertion between nucleotides c.1579_1580 on exon 14 (c.1579_1580insA) (Fig. [2f](#Fig2){ref-type="fig"}), resulting in a frameshift mutation (p.Arg527Xfs), which has ever been reported in three Asian families \[[@CR30]--[@CR32]\]; while the proband and his father in F2 carried a one-base-substitution of C by T at nucleotide c.649 on exon 7 (c.649C \> T) (Fig. [4d, e](#Fig4){ref-type="fig"}), resulting in a nonsense mutation (p.Gln217X), which was once recovered in a French family \[[@CR22]\]. In addition, there are no mutations detected in the control subjects (II10, III10, III11, III13, IV2).

Discussion {#Sec7}
==========

Studies of patients with Birt-Hogg-Dubé syndrome are very rare especially in Asian countries.

In this study, we described two BHDS families and applied whole exome sequencing and Sanger sequencing to explore the genetic mutations. Patients from family 1 mostly suffered from pneumothorax and pulmonary cysts, several of whom also mentioned skin lesions or kidney lesions. While in family 2, only thoracic lesions were found in the patients, without any other clinical manifestations. Two *FLCN* mutations have been identified: One is an insertion mutation (c.1579_1580insA/p.R527Xfs) previously reported in three Asian families (one mainland family and two Taiwanese families); while the other is a firstly reviewed mutation in Asian population (c.649C \> T/p.Gln217X) that ever been detected in a french family.

As we have reported above, patients from these two families were mostly characterized by pneumothorax, and even without any other clinical manifestations, which may remind us of BHDS and carrying out genetic tests for patients with familial pneumothorax history. However, the exact mechanism of this syndrome is still unclear till now. Our study could only expand the spectrum of *FLCN* mutations ethnically, there are still many aspects of BHDS to be explored.

Conclusions {#Sec8}
===========

Our detection of these two mutations expands the spectrum of *FLCN* mutations and will provide insight into genetic diagnosis and counseling of Birt-Hogg-Dubé syndrome.

BHDS

:   Birt-Hogg-Dubé syndrome
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